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Because of the difficulties associated with obtaining
patient samples and the labile nature of some analytes,
manufacturers will always require the assistance of clinical
chemistry laboratories in the establishment of performance
claims, but our experience suggests that this work should
not be undertaken lightly by laboratories and that manu-
facturers would be advised to assess the resources of any
chosen site carefully before proceeding.
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Introduction
The previous paper [2] described two method comparison
studies which followed the guidelines of the National
Committee for Clinical Laboratory Standards protocol
PSEP-4, comparison of methods experiment ]. The Kodak
Ektachem analytical system for urea and glucose was com-
pared with Technicon AutoAnalyzer methodologies. Two
hundred patient samples distributed according to PSEP-4
guidelines were analysed in duplicate by the test and com-
parative methods. Twice the minimum recommended number
of patient samples were used in order to study the effect
of sample size above as well as below the recommended
minimum number. The data for glucose is presented and the
data modified to produce changes in the sample number,
distribution and range.
The estimates of slope, intercept and standard error of the
estimate of y (Syx) from linear regression analysis are used in
the calculation of the tolerance limits and in estimates of
total error at medical decision levels, which provide a basis
for manufacturers’ performance claims. This paper illustrates
the way in which sample number, distribution and range
could alter the manufacturers’ performance claims and gives
an indication of the magnitude of these effects. The methods
adopted for detection of outliers in the data can also have a
marked effect on the claims made.
Materials and methods
Experimental methods and materials for glucose have been
described previously [2]. The distribution of patient samples
recommended for glucose analysis was Group A (<2.8
mmol/1) 10%; B (2.9-6.1 mmol/1) 40%; C (6.2-8.3 mmol/1)
30%; D (8.4-13.8 mmol/1) 10%; and Group E (>13.8 mmol/1)
10%. The information in the draft version of the PSEP-4
protocol contained a misprint and groups for glucose were
given as A (10%), B (40%), C (20%, D (10%) and E (10%). In
our experiment 20% of samples were-collected in Group E.
However, the recommended distribution and our distribution
have been compared with other possible distributions for one
hundred samples by data modification described below.
The equations for linear regression analysis were those
given in Davies et al [3]. Modification of the original data
base of two hundred samples analysed in duplicate by test
and comparative method is described below.
Range of samples
The results were divided into their five separate groups
(A-E) and modified data sets for linear regression analysis
provided by increasing range from low concentrations, A, AB,
ABC, ABCD, ABCDE and from high concentrations, E, DE,
CDE, BCDE, ABCDE and from mid concentrations, C, BCD,
ABCDE.
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Table 1. Distribution of 100 samples prepared from the
original data set of 200
Range category (%)
A B C D E
C 10 60 10 10 10
C2 20 40 20 10 10
C3" 10 40 30 10 10
C4 ** 10 40 20 10 20
c5 20 20 20 20 20
c6 10 10 20 20 40
* Distribution recommended in PSEP-4
** Distribution used in original method comparison study [2].
Number of samples
In order to reduce the data from 200 paired duplicate
sample analyses to 150, 100 and 50, the samples were first
ranked in ascending order based on the mean value of the
duplicate analyses by the comparative method. The
samples were then numbered in sets of four in ascending
order 1, 2, 3, 4; 1, 2, 3, 4 etc. Consequently, if 150 samples
were required, the first three samples in each set were ex-
tracted, if 100 samples were required the first two samples in
each set were extracted, and so on.
Distribution of samples
From the complete data of 200 paired duplicate sample
analyses, six sets of 100 paired duplicate samples could be
prepared using the approach described above. The distrib-
utions prepared and their designations are given in Table 1.
C3 is the distribution recommended by the protocol and C4
Table 2.. Linear regression data on different data sets
the distribution which forms the whole data base in this
study.
Single analyses of samples
Each sample was analysed in duplicate by the test method
(Y1Y2) and the comparative (X1X2) method and therefore
four possible combinations of single rather than duplicate
analyses could be prepared:
X1 Y 1;X2 Y1;X1 Y2andX2Y2.
Detection of outliers
Tests for detection of outliers,and exclusion results outside
the range of each method were used as recommended in
PSEP-4 and discussed more fully in a previous publication.
Results
The whole data base as an X/Y plot with the comparative
method as the independent variable X was illustrated in a
previous paper [2]. Visual inspection reveals no obvious
non-linearity in the data. Figure shows the same data with
the comparative method as the independent variable but the
vertical axis being the bias of each individual test value from
the comparative method (Y-X). Each test and comparative
method value is the mean of duplicate determinations and
the range of groups A to E is indicated.
Table 2 gives the linear regression estimates and Table 3
calculations of bias, tolerance limits and total error at a
medical decision level of 6.6 mmol/1 for those data sets
which might be realistically encountered in an experimental
situation.
Data sets al al relate to the range of samples, b -b4
to number of samples, Cl c_6 to the distribution of samples,
Designation No of Groups
of data set samples represented Slope SD Intercept SDx Greater than SD Syx x Sy--’- 3.5 times Syx
al 20 A 1.005 0.062 -0.119
a2 100 AB 0.957* 0.019 +0.004
a3 140 ABC 0.963* 0.013 -0.024
a4 160 ABCD 0.979* 0.009 -0.099
a5 40 E 0.975 0.019 +0.322
a6 60 DE 0.993 0.012 -0.108
a7 100 CDE 1.000 0.007 -0.260*
a8 180 BCDE 0.997 0.005 -0.200*
a9 40 C 1.049 0.068 -0.662
al0 140 BCD 0.082 0.012 -0.124
al 200 ABCDE 0.996 0.004 -0.178*
b 50 ABCDE 0.983* 0.007 -0.077
b2 100 ABCDE 0.995 0.006 -0.185"
b3 150 ABCDE 1.000 0.005 -0.211"
b4 200 ABCDE 0.996 0.004 -0.178*
cl 100 ABCDE 0.984* 0.006 -0.120"
c2 100 ABCDE 0.983* 0.006 -0.130
c3 100 ABCDE 0.984* 0.006 -0.140"
c4 100 ABCDE 0.995 0.006 -0.185"
c5 100 ABCDE 0.994 0.006 -0.163"
c6 100 ABCDE 0.997 0.006 -0.190"
dl 200 ABCDE 0.996 0.004 -0.162"
d2 200 ABCDE 0.994 0.004 -0.216"
d3 200 ABCDE 0.996 0.004 -0.138"
d4 200 ABCDE 0.995 0.004 -0.192"
d5 200 ABCDE 0.996 0.004 -0.178*
el 200 ABCDE 0.996 0.004 -0.178"
e2 178 ABCDE 1.011 0.006 -0.276*
e3 177 ABCDE 1.005 0.006 -0.238*
0.119 0.184 0.9699 3.73 1.82 0
0.087 0.278 0.9806 5.20 4.27
0.071 0.289 0.9878 6.57 5.15
0.057 0.295 0.9934 8.84 5.85 0
0.406 0.657 0.9927 8.36 20.47 0
0.212 0.575 0.9961 11.30 17.21 0
0.105 0.487 0.9976 14.36 13.27 0
0.054 0.415 0.9981 16.16 9.55
0.506 0.315 0.9278 2.34 7.36 0
0.079 0.309 0.9904 7.29 6.43 0
0.046 0.397 0.9983 17.02 8.77 2
0.082 0.354 0.9986 19.20 8.78 0
0.064 0.392 0.9983 17.30 8.72
0.055 0.409 0.9982 16.55 8.77 2
0.046 0.397 0.9983 17.02 8.77 2
0.050 0.304 0.9983 17.57 6.91 0
0.048 0.299 0.9985 18.34 6.91 0
0.056 0.320 0.9981 16.35 7.44 0
0.064 0.392 0.9983 17.30 8.72
0.065 0.394 0.9884 17.65 9.05
0.091 0.480 0.9981 16.32 12.50
0.046 0.397 0.9983 17.04 8.74 2
0.046 0.398 0.9983 17.01 8.80 2
0.049 0.419 0.9981 16.14 8.74
0.049 0.422 0.9980 16.01 8.80 2
0.046 0.397 0.9983 17.02 8.77 2
0.046 0.397 0.9983 17.02 8.77 2
0.053 0.349 0.9966 12.00 7.25
0.050 0.330 0.9968 12.30 7.18 0
* p( 0.05
Data sets d d4 are based on single rather than duplicate analyses by both methods
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d ds to single rather than duplicate estimations by each
method and el ea to the exclusion of samples outside the
range of each method without dilution and to exclusion of
outliers. Data sets aa 1, b4, ds and el are identical and are
included for ease of comparison in Table 2.
Discussion
The NCCLS protocol, PSEP-4, states that "Inaccuracy is
quantitated by the estimates of bias at various medical
decision concentrations, Xc, and by estimation of total
error at the medical decision concentration closest to the
mean of the comparison of methods data". The bias of a test
method at concentration Xc is calculated, bias Yc- Xc
whereYc is the predicted value at Xc and is given by a + b x c
(the estimate of intercept is given by ’a’ and of slope by ’b’).
Clearly any factors which influence the estimates of slope
and intercept are important in this context and the
magnitude of the standard deviations of these estimates will
determine the confidence which can be attached to them.
The tolerance limits are calculated and used to estimate
the expected total error. The tolerance limits for a desired
population proportion (p) and specified confidence (3’) may
be calculated at Xc from the equation given in PSEP-4
xJ"
(Xc )2
Yc+KSy +N+ 2;(Xi-)2
where K is the appropriate tolerance factor for a normal
distribution (K values for 3’ 0.99 p 0.95 are used in this
study) and Syx is the standard error of the estimate of y.
Tolerance limits are calculated only for the medical decision
concentration closest to the mean of the comparison of
methods data. Total error is calculated by taking the differ-
ences between the tolerance limits and Xc and the absolute
value of the largest difference is taken as the estimate of total
error.
It can be seen that estimates of slope and intercept will
influence the calculation of the predicted value Yc and that
the magnitude of Syx will affect the tolerance limits and
total error. The value of K is influenced by the number of
samples used.
Previous authors [3,4,5] have drawn attention to the
effects of range and numbers of samples on various linear
regression parameters. Slope s used in the calculation of
Yc and different estimates of the slope are obtained with
changes in range aa aa and distribution of data ca -c6.
The confidence attached to the estimates of slbpe (which
decide whether the slope is significantly different from
1.0) is affected randomly in this comparison of methods by
range (aa aal) and increased by numbers of samples (bl
b4). The use of single (da d4) instead of duplicate (ds)
analyses has a negligible effect in this set of data since only
four out of 200 duplicate estimations were greater than the
interval of 3.27 times the average absolute difference as
recommended in PSEP-4. An additionally important advan-
tage of duplicates is their value in the study of precision
profiles (Table 4).
The sign and magnitude of the intercept can also be
shown to be influenced by range and distribution of data.
No definite trend is apparent when range is extended (a
al ).but when the distribution is altered (ca c6)there was
an increasing negative intercept related to the changing slope.
The difference found between the intercept obtained for
duplicate observations (ds) and various combinations of
single observations (da d4) has little effect.
Range has no effect on Syx if the error in the data is
constant throughout the range chosen for method comparison.
Many clinical chemistry assays exhibit an increase in standard
deviation with increasing analyte concentration. Precision
profiles for glucose on theAutoAnalyzer and Kodak Ektachem
show increasing imprecision (Table 4). Syx increases as more
high concentration samples are included in the distribution
(ca c6) and is also a function of range (aa as) (Table 2)
with consequent effects on estimates of tolerance limits and
total error. Syx, the error about the regression line, is inde-
pendent of sample size [3] and this is illustrated in Table 2,
b2 b4.
Sample size has very little effect on linear regression
parameters but range and distribution can have effects on
slope, intercept and Syx. This is illustrated by the values
observed for the calculation of total error in Table 3, which
combines slope, intercept and Syx. For example, a change in
sample size b2, ba and b4 has less effect on total error than
a change in distribution of samples ca -c6 and in range of
samples a4, a8, al 0 and al 1.
The establishment of performance claims by manufact-
urers as described by the NCCLS includes a comparison of
Table 3. Bias, tolerance limits and total error at a medical decision level of 6.6 mmol/1
Designation No of Groups x Yc (Xc 6.6 Bias Tolerance limits Total
of data set samples represented Barnett) Yc" Xc error
a4 160 ABCD 5.85 6.36 -0.24 5.69- 7.03 0.91
a8 180 BCDE 9.55 6.38 -0.22 5.45- 7.31 1.15
al0 140 BCD 6.43 6.36 -0.24 5.66- 7.06 0.94
all 200 ABCDE 8.77 6.39 -0.21 5.51- 7.27 1.09
b2 100 ABCDE 8.72 6.38 -0.22 5.46- 7.30 1.14
b3 150 ABCDE 8.77 6.38 -0.22 5.46- 7.31 1.15
b4 200 ABCDE 8.77 6.39 -0.21 5.51 7.27 1.09
cl 100 ABCDE 6.91 6.37 -0.23 5.65- 7.09 0.95
c2 100 ABCDE 6.91 6.36 -0.24 5.64- 7.08 0.96
c3 100 ABCDE 7.44 6.36 -0.24 5.60- 7.12 1.00
c4 100 ABCDE 8.72 6.38 -0.22 5.46- 7.30 1.14
c5 100 ABCDE 9.05 6.40 -0.20 5.48- 7.32 1.12
c6 100 ABCDE 12.50 6.39 -0.21 5.26- 7.52 1.34
dl 200 ABCDE 8.74 6.41 -0.19 5.53- 7.29 1.07
d2 200 ABCDE 8.80 6.35 -0.25 5.47- 7.23 1.13
d3 200 ABCDE 8.74 6.44 -0.16 5.51 7.37 1.09
d4 200 ABCDE 8.80 6.38 -0.22 5.44- 7.32 1.16
d5 200 ABCDE 8.77 6.39 -0.21 5.51 7.27 1.09
el 200 ABCDE 8.77 6.39 -0.21 5.51- 7.27 1.09
e2 178 ABCDE 7.25 6.40 -0.20 5.62 7.18 0.98
e3 177 ABCDE 7.18 6.39 -0.21 5.65- 7.13 0.95
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Table 4. Imprecision at different analyte concentrations
for the comparative (AA1) and test (Kodak) methods
Auto Analyzer 1
Group SD (mmol/1) mean (mmol/1)
A 0.055 1.82
B 0.070 4.88
C 0.098 7.36
D 0.133 10.71
E 0.137 20.47
Kodak
Group SD (mmol]l) mean (mmol/1)
A 0.029 1.70
B 0.054 4.69
C 0.083 7.06
D 0.099 10.43
E 0.198 20.27
methods experiment (PSEP-4) to provide information
concerning bias and total error,which are derived from linear
regression parameters. In our studies we found that range and
distribution had the greatest influence on slope, intercept
and Syx, whereas the sample numbers studied had little
effect on these parameters. It would therefore seem appro-
priate to define a minimum range of values and suggested
distributions for individual analytes and to provide this
information in association with performance claims. Careful
inspection of graphical presentation of data is of primary
importance. The conventional XY plots of data provide the
best approach to the detection of non-linearity whereas the
presentation given in Figure where the bias of each individ-
ual test result from the comparative method is plotted against
the value for the comparative method provides a valuable
opportunity to evaluate bias between methods at different
analyte concentrations particularly as the scale of the Y axis
can be expanded as required. It would also seem appro-
priate to define the medical decision concentration for
calculation of tolerance limits and total error and chose the
concentration range and distribution to give a mean value
approximating to this concentration.
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Figure 1. Glucose comparative-method (X) and Kodak Ektachem-Comparative method (Y) for patient samples Groups ’A’ to
’E" as specified in text.
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